- ￥1600
- Sciencell
- B-7311
- 美国
- 2025年08月01日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AJE 润色服务限时 8 折起，权威机构信任 15+ 年Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 库存：
100
- 供应商：
上海酶研生物科技有限公司
- 英文名：
OEpiCM (Ovarian Epithelial Cell Medium)
- 规格：
500ml/T
|
货号 |
7311 |
|
产地 |
美国 |
|
缩写 |
OEpiCM |
|
规格 |
500ml |
|
用途 |
科研 |
|
储存 |
4度，-20度 |
|
运输 |
胶冰 |
Ovarian Epithelial Cell Medium (OEpiCM) is a complete medium designed for optimal growth of normal human ovarian epithelial cells in vitro. It is a sterile, liquid medium which contains essential and non-essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors and trace minerals. The medium is serum-free. It is HEPES and bicarbonate buffered and has a pH of 7.4 when equilibrated in an incubator with an atmosphere of 5% CO2/95% air. The medium is formulated (quantitatively and qualitatively) to provide a defined and optimally balanced nutritional environment that selectively promotes proliferation and growth of normal human ovarian epithelial cells in vitro.
1.) Friedman E. (2013) "Mirk/dyrk1B kinase in ovarian cancer." Int J Mol Sci. 14: 5560
2.) Cha Y, Kim DK, Hyun J, Kim SJ, Park KS. (2013) " TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells." Cellular Signal. 25: 1245-51.
3.) Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, Suzuki M, Sato Y. (2012) "Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis." Mol Cancer Res. 10: 1135-46.
4.) Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Mukarah AR, Weaver DW, Gruber SA, Batchu RB. (2011) "MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1." Pharm Res. 28: 3079-90.
5.) Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, Munkarah AR. (2011) "Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival." Cancer ChemotherPharmacol.68: 1273-83.
6.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kalai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenylpiperidones: differential cytotoxicity in healthy and cancer cells." Free RadicBiol Med.48: 1228-35.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验
1.) Friedman E. (2013) "Mirk/dyrk1B kinase in ovarian cancer." Int J Mol Sci. 14: 5560
2.) Cha Y, Kim DK, Hyun J, Kim SJ, Park KS. (2013) " TCEA3 binds to TGF-beta receptor I and induces Smad-independent, JNK-dependent apoptosis in ovarian cancer cells." Cellular Signal. 25: 1245-51.
3.) Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, Suzuki M, Sato Y. (2012) "Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis." Mol Cancer Res. 10: 1135-46.
4.) Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Mukarah AR, Weaver DW, Gruber SA, Batchu RB. (2011) "MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1." Pharm Res. 28: 3079-90.
5.) Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, Munkarah AR. (2011) "Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival." Cancer ChemotherPharmacol.68: 1273-83.
6.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kalai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenylpiperidones: differential cytotoxicity in healthy and cancer cells." Free RadicBiol Med.48: 1228-35.
佚名 卵巢上皮性肿瘤是最常见的卵巢肿瘤，来源于卵巢表面的上皮（体腔上皮），最常见的是囊腺瘤，主要包括浆液性和粘液性两种。 （一）浆液性肿瘤 1．良性浆液性囊腺瘤（serous cystadenoma）是浆液性肿瘤中最常见的一种，约占浆液性肿瘤的60％，多发生于20～40岁妇女，以单侧居多，也可双侧发生（约占20％）。 病变 肉眼
细胞培养的基本步骤都有哪些？复苏、传代、冻存的基本操作是什么样的？如果你刚刚开始细胞培养实验，想要建立稳定的细胞培养流程，快来听Dr. 赛的讲解吧。
ID8（别称ID8/MOSEC），来源于C57BL/6小鼠卵巢表面上皮细胞，是体外长期传代后自发转化筛选出的高成瘤性克隆，在10个候选克隆中肿瘤负荷最高。 细胞特性与应用场景 核心特性：同源性高，可在免疫健全小鼠体内成瘤；与人类上皮性卵巢癌生理特征高度相似；成瘤稳定、重复性好。 主要用途：卵巢癌免疫治疗研究、腹腔转移机制研究、化疗药物筛选、肿瘤微环境研究。 形态特征与生长方式 贴壁生长，上皮细胞样，多角形或鹅卵石形态，单层排列。生长速度偏快，换液周期2-3天，传代比例1:2至1:4，密度
技术资料暂无技术资料 索取技术资料
